Role of Chronic Inflammation in Cardiovascular Disease (CVD) and Lung Cancer
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Immunology".
Deadline for manuscript submissions: closed (31 December 2021) | Viewed by 2204
Special Issue Editor
Special Issue Information
Dear Colleagues,
Based on the American Heart Association’s 2016 Heart Disease and Stroke Statistics update; by the year 2030 approximately 40 % of US population is projected to have some form of cardiovascular disease (CVD). The recently concluded Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) trial showed that anti-IL-1β therapy can reduce CVD, independent of lipid levels. One of the interesting findings from the CANTOS trial was a retrospective analysis showing a marked reduction in the hazard ratio (HR) of lung cancer incidence in the two treatment groups (150 and 300 mg) compared with placebo controls, with a HR of 0.33 after 3.7 years of follow-up. Based on SEER cancer statistics, lung cancer accounts for 13% of all new cancer diagnoses but 24% of all cancer deaths, making it the leading cause of cancer deaths.
The delicate balance between atheroprotective pathways vs. atherogenic pathways can decide the fate of atherosclerotic plaque progression/regression. A similar scenario is observed in lung cancer where inflammation and immunosuppression confer antagonizing effects in the tumor microenvironment to modulate the interaction between immune and cancerous cells.
Given that both CVD and the lung cancer field involve multiple common pathways and are promoted by presence of chronic inflammation in humans, the idea of combining lipid-lowering therapeutics and anticancer therapy with anti-inflammatory drugs is now looking more attractive than ever. Thus, identification of the novel players involved in inflammation-mediated progression of CVD and lung cancer is of high importance. Drugs targeting these pathways can serve as stand-alone therapy or may serve as adjuvant therapy along with statin or anticancer drugs.
We invite innovative and thorough studies regarding role of chronic inflammation in CVD and lung cancer to be a part of this timely and highly impactful Special Issue in the Journal of Clinical Medicine.
Dr. Kailash Gulshan
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Inflammation
- Cholesterol
- Nlrp3 inflammasome
- IL-1b
- Pyroptosis
- Gasdermin
- Caspases
- TLRs
- NETosis
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
